aziridine-2-carboxylic acid: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 193914 |
| CHEMBL ID | 4060934 |
| MeSH ID | M0198587 |
| Synonym |
|---|
| aziridine-2-carboxylate |
| aziridine-2-carboxylic acid |
| 2-aziridinecarboxylic acid |
| 54080-06-7 |
| AKOS016003042 |
| aziridine-2-carboxylicacid |
| CS-0046239 |
| dl-2-aziridinecarboxylic acid |
| d-2-aziridinecarboxylic acid |
| FT-0712984 |
| SB15386 |
| SB15387 |
| CHEMBL4060934 |
| DTXSID50968924 |
| EN300-150862 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1469518 | Glutathione reactivity in pH 7.4 deuterated phosphate buffer at 10 mg after 20 hrs in presence of 1.5 to 2 equiv of GSH by 1H NMR analysis | 2018 | Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7 | Regio- and Stereospecific Synthesis of Oridonin D-Ring Aziridinated Analogues for the Treatment of Triple-Negative Breast Cancer via Mediated Irreversible Covalent Warheads. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (8.00) | 18.2507 |
| 2000's | 8 (32.00) | 29.6817 |
| 2010's | 11 (44.00) | 24.3611 |
| 2020's | 4 (16.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 3 (12.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 22 (88.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||